Ironwood Pharmaceuticals/IRWD

$15.18

0.99%
-
1D1W1MYTD1YMAX

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Ticker

IRWD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Thomas Mccourt

Employees

267

Headquarters

Boston, United States

IRWD Metrics

BasicAdvanced
$2.35B
Market cap
-
P/E ratio
-$6.51
EPS
0.66
Beta
-
Dividend rate

What the Analysts think about IRWD

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
36.17% upside
High $23.00
Low $18.00
$15.18
Current price
$20.67
Average price target

IRWD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-0.85% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$117.5M
3.34%
Net income
$-1M
-106.54%
Profit margin
-0.85%
-106.32%

IRWD Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 104.86%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.25
-$6.71
$0.09
-$0.01
-
Expected
$0.24
$0.25
$0.16
$0.21
$0.17
Surprise
3.09%
-2,820.27%
-42.86%
-104.86%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Ironwood Pharmaceuticals stock

Buy or sell Ironwood Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing